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Aliskiren represents the first member in a new class of
antihypertensive drugs. Inhibiting the renin–angiotensin
system at its rate-limiting step is an idea that has been
pursued for 430 years; however, earlier compounds failed
because of problems related to efficacy, bioavailability,
and/or side effects. Aliskiren, a 610 Da nonpeptide molecule,
has exceptional affinity for the human renin enzymatic site
and a half-life of about 40 h, which make its 3%
bioavailability clinically unimportant with continued
administration. The drug is not metabolized by CYP P450
enzymes and is excreted 490% unchanged by the fecal
route. No adjustments are necessary for renal function, liver
function, age, ethnicity, or other prescribed drugs. Blood
pressure reductions are similar to those provided by other
monotherapies. Interestingly, aliskiren combined with
angiotensin receptor blocker or angiotensin-converting
enzyme inhibitor therapy leads to a further blood pressure
reduction as does combination with a diuretic or calcium
channel blocker. The fact that plasma renin activity is
reduced to low levels with aliskiren could provide a
theoretical advantage over other treatments, while increases
in total renin (prorenin) after the drug poses additional food
for thought. Studies with primary cardiovascular and renal
end points to address these possibilities are in progress.
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PHARMACOLOGY
Excellent comprehensive reviews on oral renin inhibitors
have been published recently.1 The readership is well familiar
with the renin–angiotensin system, the functional cascade,
and notions on peptides and enzymes beyond angio-
tensin (Ang) II that are discussed in detail elsewhere.2
Aliskiren, (2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-
5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxy-
propoxy)phenyl]-octanamide hemifumarate), or C30H53N3O6
(Figure 1), is a nonpeptide direct renin inhibitor.3 The
molecule occupies specific subsites within the enzymatic
pocket of the renin molecule, thereby blocking the function
of the enzyme. Aliskiren is a hydrophilic molecule with high
aqueous solubility. Aliskiren exhibits a high specificity for
human renin over other human aspartic peptidases (10 000-fold
lower affinity) or non-human renins. For instance, the IC50
values for human renin (0.6) are superior compared to those for
marmoset renin (2), rat renin (80), pig renin (159), or cat renin
(8500); these findings underscore the drug’s species specificity.
The species specificity also explains why aliskiren was first
investigated in the marmoset, a most difficult animal model,
and subsequently in transgenic rats outfitted with the human
renin and human angiotensinogen transgenes.4–6
Renin is released as an active enzyme by the kidney and as
prorenin by other tissues, including the eye, testis, ovary,
adrenal gland, salivary gland, and mast cells.7 Prorenin
features a 43 amino-acid N-terminal handle region that
covers the enzymatic site. A prorenin/renin receptor has been
cloned that is expressed by numerous cell types. When
prorenin occupies this receptor, the molecule is activated
through an opening of the handle region and is then capable
of cleaving angiotensinogen. Aside from activating prorenin,
the renin receptor also signals via the ERK1/2 (extracellularly
regulated kinase) pathway (Figure 2). The prorenin/renin
receptor and its signaling is an extremely interesting area of
research and is reviewed elsewhere.8 Aliskiren blocks the
enzymatically active site of renin. There is no evidence that
aliskiren blocks the prorenin/renin receptor or its signaling
pathway (DN Mu¨ller, personal communications, 2007).
However, when prorenin is activated by docking to the
receptor, aliskiren can, of course, occupy the enzymatic
pocket and block the activated renin.
In patients and animal models treated with aliskiren,
plasma renin activity (PRA), namely the amount of Ang I
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generated per h, is reduced to low values. Ang II concentra-
tions are also reduced and aldosterone concentrations are
significantly decreased. However, total renin, which can now
be measured by an immunoradiometric assay, is increased.
Kang et al.9 have published dramatic multiphoton fluo-
rescence micrographs of afferent arterioles of animals receiving
angiotensin-converting enzyme (ACE) inhibition, AT1 re-
ceptor blockade (ARB), or aliskiren. ACE inhibitors and ARB
increase PRA, whereas aliskiren reduces PRA at the afferent
arteriole. The significance of increased total renin, or reduced
PRA, after aliskiren treatment is not entirely clarified. Sealey
and Laragh10 have hypothesized that the increase in total
renin might pose some cardiovascular risk (see below).
Menard and Azizi11 have argued against that possibility.
Aliskiren exhibits interesting kinetics.12–19 The drug half-
life is about 40 h. Thus, a plateau is reached after about
a week’s ingestion to concentrations of about 350 ng ml1.
The half-life is not influenced by renal function or liver
function, even though the biliary tract is the principle mode
of elimination. No effect of ethnicity was shown when
Japanese and Caucasian subjects were compared. Aliskiren
kinetics were measured in the presence of various other
drugs, including irbesartan, lovastatin, atenolol, celecoxib,
furosemide, and cimetidine; no interactions were demons-
trated with the exception that irbesartan reduced the Cmax of
aliskeren by 50% and aliskeren reduced the area under
the curve (AUC) and Cmax of furosemide. When aliskeren was
administered with a high-fat meal, both the AUC (70%) and
Cmax (85%) of aliskeren were reduced. Aliskiren is not
metabolized by CYP P450 enzymes and is only slightly
methylated and hydroxylated. The vast bulk of ingested drug
is eliminated in the stool, as the bioavailability of the drug is
only about 3%. Aliskiren is extremely well tolerated and the side
effect profile has equaled placebo in all trials reported to date.
PROOF OF THE PUDDING
That is all very nice, but how well does aliskiren lower blood
pressure (BP)? Gradman et al.20 performed a randomized,
multicenter, double-blind, placebo-controlled, active-com-
parator, eight-week trial in patients with mild-to-moderate
hypertension, in which 652 patients were randomized to
receive double-blind treatment with once daily oral doses of
aliskiren (150, 300, or 600 mg), irbesartan 150 mg, or
placebo. Aliskiren 150, 300, and 600 mg effectively lowered
both trough mean sitting diastolic BP (DBP) and systolic BP
(SBP). For trough DBP, the values were 9.3, 11.8, and
11.5 mm Hg, respectively, vs 6.3 mm Hg for placebo. Reduc-
tions in trough SBP were 11.4, 15.8, and 15.7 mm Hg,
respectively, vs 5.3 mm Hg for placebo. The antihypertensive
effect of aliskiren 150 mg was similar to that of irbesartan
150 mg. Aliskiren 300 and 600 mg lowered mean sitting DBP
significantly more than irbesartan 150 mg. The emphasis on
DBP was not the manufacturer’s idea. Instead, DBP still
receives much attention in all clinical trials, as the importance
of SBP, compared to DBP, has not yet filtered down to the
Food and Drug Administration requirements for demonstra-
tion of antihypertensive efficacy.
Oh et al.21 studied patients with mean sitting DBP
95–109 mm Hg. They were randomized to aliskiren 150, 300,
or 600 mg or placebo once daily for 8 weeks. The patients
then entered a 2-week, treatment-free, withdrawal period. In
total, 672 patients were randomized to treatment. After 8
weeks, aliskiren 150, 300, and 600 mg reduced mean sitting
SBP/DBP by 13.0/10.3, 14.7/11.1, and 15.8/12.5 mm Hg,
respectively, vs 3.8/4.9 mm Hg for placebo. The BP-lowering
effect of aliskiren persisted for up to 2 weeks after treatment
withdrawal. This study is of interest because of the
continuous observation after treatment withdrawal. The
results would suggest that the concerns expressed by Sealey
and Laragh10 are unfounded.
Kushiro et al.22 randomized 455 Japanese men and women
with a mean sitting DBP of 95–110 mm Hg to aliskiren 75,
150, or 300 mg or placebo. The placebo-corrected reductions
in mean sitting SBP/DBP were 5.7/4.0, 5.9/4.5, and
11.2/7.5 mm Hg in the aliskiren 75, 150, and 300 mg groups,
respectively. Weir et al.23 have recently summarized the
observations in multiple clinical trials with aliskeren by
pooling the study observations. Among more than 7000




























Figure 2 | Prorenin features a handle region that blocks the
enzymatic pocket. Active renin is released from the kidney,
without the prosegment. Otherwise, prorenin is released from
other sites that can be activated proteolytically (freezing or acid
treatment) or nonproteolytically by binding to the prorenin/renin
receptor. When bound to the receptor, the handle region opens
and renin can locally cleave angiotensinogen. The renin receptor
also signals via ERK1/2.
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antihypertensive efficacy of aliskeren was independent of age,
race, or sex.23 Jordan et al.24 studied obese patients with
hypertension (BMI (body mass index)X30 kg m2) who had
not responded to 4 weeks of treatment with hydrochlor-
othiazide (HCTZ) 25 mg. A total of 560 patients received
single-blind HCTZ (25 mg) for 4 weeks; 489 nonresponders
were then randomly assigned to double-blind aliskiren
(150 mg), irbesartan (150 mg), amlodipine (5 mg), or placebo
for 4 weeks added to HCTZ (25 mg), followed by 8 weeks on
double the initial doses of aliskiren, irbesartan, or amlodi-
pine. After 8 weeks of double-blind treatment (4 weeks on
the higher dose), aliskiren/HCTZ lowered SBP/DBP by 15.8/
11.9 mm Hg, compared to placebo/HCTZ (8.6/7.9 mm Hg).
However, irbesartan/HCTZ and amlodipine/HCTZ led to
similar reductions (15.4/11.3 and 13.6/10.3 mm Hg, respec-
tively). Adverse event rates were highest with amlodipine/
HCTZ because of a higher incidence of peripheral edema
(11.1 vs 0.8–1.6% in other groups). Thus, aliskiren provides
reliable SBP/DBP reductions in various patient groups,
including the obese hypertensive patient.
Villamil et al.25 randomized 2776 patients to receive
aliskiren (75, 150, or 300 mg), HCTZ (6.25, 12.5, or 25 mg),
the combination of aliskiren and HCTZ, or placebo, in a
factorial design. The primary end point was the change in
SBP/DBP from baseline to week 8. PRA was assessed at these
time points. Aliskiren soundly beat placebo. Combination
treatment was superior to both component monotherapies in
reducing SBP/DBP 21.2/14.3 mm Hg from baseline. Aliskiren/
HCTZ 300/25 mg resulted in more responders and better
control rates than either monotherapy. PRA was reduced by
65–72% from basal values.
Oparil et al.26 randomized 1797 hypertensive patients with
DBP 95–109 mm Hg and 8-h daytime ambulatory DBP
(X90 mm Hg) to aliskiren 150 mg (n¼ 437), valsartan
160 mg (455), a combination of aliskiren 150 mg and
valsartan 160 mg (446), or placebo (459) for 4 weeks,
followed by forced titration to double the dose to the
maximum recommended dose for another 4 weeks. At week 8
end point, the combination of aliskiren 300 mg and valsartan
320 mg lowered mean sitting DBP from baseline by
12.2 mm Hg, more than either monotherapy (aliskiren
300 mg, 9.0 mm Hg decrease; valsartan 320 mg, 9.7 mm Hg
decrease) or with placebo (4.1 mm Hg decrease). Adverse
events and laboratory abnormalities were similar in all
groups. The authors also focused on total renin, which
increased with both drugs but more so with aliskiren; PRA,
which decreased with aliskiren but increased with valsartan;
and aldosterone, which decreased with valsartan and with the
combination. Thus, the combination of aliskiren and
valsartan at maximum recommended doses lowered BP
further in patients with hypertension, with a tolerability
profile similar to that with either drug alone. Other trials
have demonstrated greater BP reduction with the combina-
tion of aliskeren plus amlodipine and aliskeren plus ramipril
compared to monotherapy, thus extending the drug combi-
nations that have been studied.23
What are the adverse effects that have emerged from these
trials with this novel antihypertensive agent? From the pooled
analysis of studies reported to date, the evidence indicates a
reported side effect profile no different than placebo.23
Headaches were reported less frequently with aliskeren than
with placebo.23 On the other hand, a dose-dependent
incidence of diarrhea was observed with aliskeren, particu-
larly at the 300 and 600 mg day1 doses.23
These are the major studies published to date (August
2007) on the efficacy of aliskiren. In all fairness, substantially
more clinical data have been presented at scientific meetings
and published in abstract form. Information on proteinuria
reduction in diabetic patients is also available; aliskiren
reduces proteinuria. What can we deduce from the informa-
tion at hand? Aliskiren as monotherapy reduces SBP/DBP as
well as any other antihypertensive drug as monotherapy. The
kinetics are foolproof; doing harm with aliskiren, other than
women contemplating pregnancy of course, appears to be
difficult. Aliskiren is efficacious in a broad range of
hypertensive subjects. Aliskiren works well in combination
with HCTZ. Aliskiren and valsartan at maximum package
insert doses when combined lower BP further. Other
efficacious combination therapy with aliskeren includes
amlodipine and ramipril. Aliskiren reduces circulating Ang
I, Ang II, aldosterone, and PRA. Aliskiren increases circulat-
ing total renin concentration. Longer trials addressing issues
of target organ damage and degree of proteinuria reduction
are running or are nearing completion. These exciting
findings should be tempered with the realization that the
studies conducted so far have been relatively short term and
do not include any information regarding outcomes.
WHO NEEDS IT?
The same question was asked when ARBs were introduced, as
ACE inhibitors dominated the scene. Some purists still insist
that ARBs are indicated solely for coughing patients;
however, prospective randomized trials and the placebo-
similar side effect profiles have convinced most clinicians that
ARBs are useful. Direct renin inhibitors need to be tested.
They lower Ang II and aldosterone concentrations. Whether
‘escape’ is possible remains to be seen. Although cathepsins
have been implicated in Ang II generation in vitro, a relevant
in vivo role has not been shown to our knowledge.27
The same can be said for tonin.28 When aliskiren was given
‘on top’ of valsartan or an ACE inhibitor, a further decrease
in BP was observed.23,26 Conceivably, this additional
renin–angiotensin system blockade would not have occurred
had the ARB or ACE inhibitor dosage been higher in these
patients. However, an additional avenue of blockade remains
possible. Alderman et al.29 have implicated PRA as an
independent risk factor, probably because PRA reflects Ang II
levels. However, their population had not been treated. What
high PRA levels mean in treated hypertensive patients is
unclear—probably not much. The tolerability of aliskiren has
been superb in the trials; the pharmacokinetics and lack of
drug interactions are extremely attractive. However, aliskiren
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would be expected to cause the same problems as any
renin–angiotensin system inhibition strategy, including
relevant decreases in renal function in patients with vascular
disease and hyperkalemia. Contraindication in pregnancy or
in women contemplating such a move is a given. Time and
future studies will tell.
FOOD FOR THOUGHT
Robert Tigerstedt and Bergman30 would be bemused to see
where their initial discovery of renin has led. The renin–an-
giotensin system has been a never-ending story with many
new beginnings. One story warranting more discussion here
concerns prorenin and the prorenin/renin receptor that were
briefly mentioned earlier. Luetscher and co-workers31,32
published two remarkable papers 20 years ago showing that
diabetic target organ complications correlate not with PRA
but rather with prorenin, a proenzyme that at that time had
no known additional biological function or activity. Since
then, we have learned that diabetics, in particular, appear to
benefit from renin–angiotensin system blockade, even though
their PRA values are low rather than high. Interestingly,
prorenin is also made in the eye, a particularly important
diabetic target organ.33 The prorenin/renin receptor may be
important here (Figure 2).34,35 The receptor activates
prorenin locally at the tissue level. No evidence has been
shown that aliskiren blocks the interaction between prorenin
and the prorenin/renin renin receptor. However, aliskiren
would be anticipated to be very effective in preventing
activated prorenin from cleaving angiotensinogen to generate
Ang I locally. The ‘tissue renin–angiotensin system,’ as we
currently understand it, would be expected to be blocked by
such an effect. The prorenin/renin receptor is activated with
equal facility by both renin and prorenin.
Although aliskiren lowers PRA, the concentration of the
enzyme renin, as Oparil et al.26 have observed, increases to
high levels. High renin concentrations could conceivably
interact with the prorenin/renin receptor. This activation
could initiate ERK1/2 signaling, transforming growth factor-
beta (TGF-b) activation, and other potentially serious
consequences. Sealey and Laragh10 alluded to this possibility,
although they presented no data to this issue. Deleterious
effects signaled by the prorenin/renin receptor have not been
observed in animal models and neither have they been
described in patients. Nevertheless, Ichihara and co-
workers35,36 have published an exciting series of papers
suggesting that prorenin could raise havoc independent of
Ang II generation by signaling via the prorenin/renin
receptor (Figures 2 and 3). Ichihara and co-workers37–42
have produced a decoy protein that blocks the development
of diabetic nephropathy and eye changes in models
independent of Ang II generation. As a matter of fact, their
models include AT1 receptor gene-deleted mice that cannot
signal via the AT1 receptor. These findings are provocative
and controversial and indicate that much more work needs to
be done.43 However, such signaling would not be amenable to
ACE inhibitor, ARB, or direct renin inhibitor (aliskiren)
therapy. Whether or not the future is bright remains to be
seen. Nonetheless, it is certain to not be dull!
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